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Abstract
Background: Hepatocellular carcinoma (HCC) with a tumor thrombus in the inferior vena cava (IVC) and right atrium
(RA) rarely occurs and is usually associated with extremely poor prognosis, we carried out this study to evaluate the
efficacy and safety of a combination of trans-arterial chemoembolization (TACE) and external beam radiation therapy
(EBRT) in the treatment of HCC with a tumor thrombus in the IVC and RA.
Methods: From September 2005 to September 2008, 11 cases of HCC with a tumor thrombus in the IVC and RA were
treated with a combination of TACE and EBRT. Clinical adverse events, laboratory toxicity, and survival were
retrospectively studied.
Results: Thirty-one interventional procedures were conducted and EBRT was performed 11 times. All treatments
were successful and without significant complications. No severe adverse effects were observed. The median survival time
of the 11 cases was 21.0 months. One patient was monitored for 97 months and no recurrence was observed.
Conclusion: The combination of TACE and EBRT can be safely performed and may improve the prognosis of the HCC
cases with a tumor thrombus in the IVC and RA.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
monly diagnosed cancer and the third most common
cause of cancer-related death worldwide [1, 2]. Although
vascular invasion is a feature of HCC, most of the cases
are HCC with portal vein tumor thrombus [3, 4]. HCC
with an extension to the inferior vena cava (IVC) and
right atrium (RA) rarely occurs and is usually associated
with extremely poor prognosis.
HCC that has invaded into the IVC and RA is usually
treated with surgery, radiotherapy (RT), trans-arterial
chemoembolization (TACE), and chemotherapy.
However, the standard treatment modality has not been
established. Although TACE is a relatively safe treatment
procedure, its therapeutic effect, especially for tumor
thrombi in IVCs and RAs, remains unsatisfactory [5, 6].
A few studies have shown that the combination of TACE
with RT may improve therapeutic responses [7, 8]. There-
fore, in the present study, we retrospectively investigated 11
HCC patients with an IVC and RA tumor thrombus who
underwent the combination treatment of trans-arterial che-
moembolization (TACE) and external beam radiation ther-
apy (EBRT). In our combination therapy protocol, TACE
was used to treat intrahepatic lesions and tumor thrombus,
and EBRT was exclusively applied to the tumor thrombus
in the IVC and RA. The purpose of the present study was
to demonstrate the safety and efficacy of the combination
of TACE and EBRT in the treatment of patients with highly
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advanced HCC with a metastatic IVC and RA tumor
thrombus.
Methods
Patients and treatment protocol
Between September 2005 and September 2008, a total of 11
patients who were diagnosed with advanced HCC with IVC
and RA tumor thrombus were treated by a combination of
TACE and EBRT. The retrospective analysis of the data
was approved by Chinese PLA General Hospital investiga-
tional review board.
Pre-treatment evaluation consisted of a complete history
and physical examination, blood cell count, liver and renal
panels, AFP value, computed tomography (CT) scan of
the chest, tri-phase CT scan or dynamic magnetic reson-
ance imaging (MRI) of the liver, and total body bone scan.
Fluorodeoxyglucose positron emission tomography (PET)
or PET/CT scans were optional.
Treatments were performed when no contraindications
were identified. The treatment protocol started with 2–3
sessions of TACE (interval: 1 month), depending on the
intrahepatic tumor burden. Two weeks after TACE, EBRT
was conducted to target the IVC and RA tumor thrombus.
Patients were followed up every 3 months to check
whether new tumor lesions in the liver had developed.
When lesions were detected, TACE was performed again
to control intrahepatic lesions.
Treatment
All TACE procedures were performed using digital subtrac-
tion angiography (DSA) guidance. After a routine preopera-
tive preparation, TACE was performed under sterile
conditions, with the patient under local anesthesia. The
right femoral artery was cannulated using a 4 F vascular
sheath (Radifocus Introducer II; Terumo Corp., Japan) by
Seldinger’s technique. Selective angiography of the celiac ar-
tery, superior mesenteric artery and inferior phrenic artery
was performed using a 4 F hepatic artery catheter (HE,
Terumo Corp., Japan) inserted through the vascular sheath.
Maximum catheter selectivity of the hepatic artery and in-
ferior phrenic artery was achieved using a microcatheter
(Progreat, Terumo Corp., Japan), with administration from
the afferent branch to the tumor lesion. Drug dosages per
procedure varied, ranging from 6–20 mL for lipiodol
(Guerbet Corp., France), 30–50 mg of doxorubicin (Pfizer
Pharmaceuticals Ltd, USA), 100–150 mg oxilaplatin
(Sanofi Pharmaceuticals Co., Ltd, France), and 8–12 mg
mitomycin (Zhejiang Hisun Pharmaceutical Co. Ltd,
China), depending on the size of the tumor lesion and
laboratory results. Lipiodol-chemotherapeutic agents
were administered until stasis, minimizing reflux into
non-target vessels. Injection was continued until near
stasis was observed in the artery directly feeding the
tumor (i.e., the contrast column should clear within 2–
5 heartbeats). Gelatin sponge or polyvinyl alcohol parti-
cles (PVA, 500–700 μm, COOK Corp., USA) was
injected as supplement when necessary.
Three days after the procedure, patients were adminis-
tered polyenephosphatidylcholine (465 mg, iv, qd, Chengdu
Tiantaishan Pharmaceutical Co., China) and glutathione
(1,800 mg, iv, qd, LaboratorioFarmaceutico C.T.S.R.L, Italy)
to normalize liver function, as well as pain killers and an
anti-emetic. On the 3rd day after the completion of
TACE, the patients were assessed for adverse effects by
undergoing a physical examination and laboratory testing
consisting of blood cell count, as well as liver and renal
panels. The patients were discharged from the hospital
when the laboratory results were determined to be within
normal range.
EBRT was initiated after the intrahepatic lesions were
controlled by TACE. EBRT was initiated 2 weeks after
the last session of TACE. All patients underwent three-
dimensional conformal radiotherapy (3D-CRT). For radio-
therapy planning, the patients underwent contrast-enhanced
CT scans in a supine position, with both arms raised
above the head. Simulation CT data was transferred to
a radiation treatment planning system (Pinnacle, The
Philips Medical System, Netherland). The clinical target
volume (CTV) included IVC and RA tumor thrombus
without primary intrahepatic disease and was defined
as the radiographically abnormal areas and noted on
the planning CT images from the diagnostic enhanced
CT and/or MRI. The 4D-CT and respiratory gating
techniques were not used in the present study. Considering
setup error and target motion, PTV was determined as
the CTV plus 5 mm for the anterior, posterior, medial,
and lateral margins, and 10 mm for the superior and infer-
ior margins. Organs at risk (OARs) included the liver,
heart, duodenum, spinal cord, and kidneys. Dose con-
straints for OARs were defined as follows: the mean dose
and V35 (Vn, the percentage of volume receiving more
than n Gy) of the liver were maintained at < 30 Gy and
50 %, respectively. The mean dose and V50 of the heart
were maintained at < 40 Gy and 50 %, respectively. The
V50 and V45 of the duodenum were maintained
at < 2 % and 25 %, respectively. The maximum dose
was maintained < 45 Gy for the spinal cord. The mean
dose for each kidney was maintained < 23 Gy. 3D-CRT
was delivered by using a linear accelerator with 10-MV
X-rays, 3–5 beams. A daily fraction of 2 Gy was admin-
istered at five fractions per week to deliver a total dose
of 60 Gy.
Evaluation
Acute and late toxicities from treatments were graded
according to NCI-CTCAE version 4.0 [9]. Responses were
defined using the mRECIST criteria [10] based on an
enhanced CT of the thorax and MRI of the liver.
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Data analyses
SPSS for Windows, version 16.0; SPSS Inc., Chicago,
Ill, USA) was used for data analysis. The duration of
OS was calculated from the diagnosis of HCC until
death or until the date of the last follow-up visit for pa-
tients still alive.
Results
The characteristics of the patients included in the study are
presented in Table 1. Radiologically confirmed complete re-
sponse (CR) of the tumor thrombus in IVC and RA was
achieved in all cases. Radiologically confirmed CR, partial
response (PR), stable disease (SD), and disease progression
(PD) for intrahepatic disease were observed in 2, 6, 2, and 1
patient, respectively, after 2–5 sessions of TACE. Metasta-
ses to organs other than IVC/RA during treatment were
observed in 9 patients: 6 had lung metastasis (1–6 months
from the first treatment), 1 had lung (3 months from first
treatment) and adrenal metastases (7 months from first
treatment), and 2 had bone metastasis (5 and 9 months
from first treatment).
Among the 9 patients (81.8 %) with metastases, 7 pa-
tients with lung metastasis were treated with systemic
chemotherapy (2 patients) and oral administration of
Table 1 Patient characteristics (at diagnosis of tumor thrombus in IVC/RA
Case Age Gender Etiology Pathology Intrahepatic tumor size (cm) AFP (μg/L) Survival time (months) Status
1 54 M Hepatitis B Moderately differentiated HCC 7 16.74 21 Dead
2 44 M Hepatitis B NA 5 322.11 97 Alive
3 30 F Hepatitis B NA 11 1210 11 Lost
4 55 M Hepatitis B Poorly differentiated HCC 6 2.01 24 Dead
5 53 M Hepatitis B NA 5 1,105 66 Alive
6 40 M Hepatitis B NA 6.5 390.68 25 Dead
7 48 M Hepatitis B Moderately differentiated HCC 10.5 >24,200 8 Dead
8 61 M Hepatitis B NA 10 1,503 9 Lost
9 74 M Hepatitis B NA 9.5 903 10 Dead
10 64 M Hepatitis B NA 9 1,842 7 Lost
11 48 M Hepatitis B NA 6.5 >20,000 36 Dead
Fig. 1 Overall survival of the entire group of patients. Median survival: 21.0 months
Duan et al. Cancer Imaging  (2015) 15:7 Page 3 of 7
sorafenib (5 patients), depending on the financial capacity of
the patient. The chemotherapeutic protocol was FOLFOX4:
oxaliplatin, 85 mg/m2, intravenous (iv.) at day 1; leucovorin
(LV), 200 mg/m2, iv. at days 1 and 2; 5-fluorouracil (5-FU),
400 mg/m2, iv. bolus and then 600 mg/m2, iv. for at least
22 h on days 1 and 2. The protocol was repeated every
2 weeks. Follow-up indicated that the treatments resulted
in poor response and lung metastases in all 7 patients.
One patient with adrenal metastasis was treated by adrenal
artery chemoembolization; follow-up images showed
that PR was achieved. Two patients with bone metastasis
were received symptomatic treatment by bisphosphonate
zoledronic acid (4 mg, iv. repeated every month).
The 1- and 3-year overall survival rates of the 11 patients
were 54.5 % and 27.3 %, respectively, and the overall
median survival duration was 21.0 months (Fig. 1). At the
time of this analysis, 6 patients (54.5 %) had died and 3
(27.3 %) patients were lost to follow-up. All patients died of
disease progression. The longest survival time was
97 months and remains alive.
Most patients experienced TACE-induced adverse effects,
which included pain, nausea, and transient reduction of
blood counts. However, severe (grades 3 or 4) adverse ef-
fects were not observed.
Discussion
With the development of treatment for HCC, survival rates
significantly improved. However, HCC with metastatic IVC
and RA tumor thrombus still has an extremely poor prog-
nosis [11, 12], and no effective therapy has been reported to
Fig. 2 Hepatic artery angiography of a 54-year-old showing a branch of the hepatic artery feeding the IVC/RA tumor thrombus (←)
Fig. 3 Right inferior phrenic artery angiography of a 55-year-old male showing an IPA-fed IVC/RA tumor thrombus (←)
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date. The median survival of patients with metastatic IVC
and RA tumor thrombus without effective therapy is
2–3 months [13].
TACE is one of the most commonly used local treatment
modalities for unresectable HCC. However, it has relative
poor efficacy in resolving tumor thrombi. Numerous clin-
ical studies have demonstrated that the combination of
TACE and EBRT may improve therapeutic responses of
HCC with PVTT [14, 15]. Therefore, it was reasonable to
postulate that a combination of TACE and EBRT may im-
prove prognoses of HCC with a tumor thrombus in the
IVC and RA. In the present study, median survival was
21 months, demonstrating that the combination treatment
is effective.
In the present study, a tumor thrombus in IVC and RA
was distinct from a portal vein tumor thrombus in that it
has a defined arterial blood supply, which included the
hepatic artery (5/11) and inferior phrenic artery (IPA)
(6/11). During the TACE procedure, we delivered lipiodol-
chemotherapeutic agents to the tumor thrombus via a
microcatheter, and follow-up images showed lipiodol de-
position (Figs. 2, 3, 4 and 5).
Historically, conventional EBRT has been infre-
quently used in the treatment of HCC because of low
Fig. 4 Enhanced CT arterial phase of a 30-year-old female showed filling-defect in IVC/RA (→)
Fig. 5 The same patient presented in Fig. 4; C-armed CT showing nice lipiodol deposition in the tumor IVC/RA thrombus after chemoembolization (→)
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tolerance of the liver for RT. However, recent advances
in radiation techniques such as 3D-CRT, image-guided
radiotherapy (IGRT), and intensity-modulated radio-
therapy (IMRT) have allowed us to deliver high doses
of EBRT to the tumor without causing dose-limiting
toxicities in the surrounding normal tissue [16, 17]. In
the present study, high-dose conformal radiotherapy
showed a significant response and acceptable toxicities
by excluding the non-tumorous volume of the liver
from the target volume.
Poor prognosis of HCC with a tumor thrombus in
the IVC/RA is strongly related to a high incidence of
metastasis and recurrence [18, 19]. In the present
study, most patients developed other organ metastases
during treatment, and therapies for metastases includ-
ing systemic chemotherapy and target therapy showed
relatively poor responses. To date, no clear modality
in preventing HCC recurrence and metastasis has been
established. Therefore, investigations on novel systemic
therapies to treat metastases are warranted [20, 21].
It is generally believed that the mechanism of IVC/RA
metastases is direct and serves as contiguous extensions of
the intrahepatic HCC [17, 22]. The growth of the tumor
thrombus involves tightly adhering to the hepatic vein and
inferior vena cava. There have been no reports on the dis-
lodgement of the thrombus, and consistent with this, no
thrombus dislodgment was noted in our study. However,
there is still a risk for thrombus dislodgment; therefore,
ultrasound was performed every 3 months to evaluate the
stability of thrombus.
The limitations of this study include the relatively
small number of patients and the use of a few compari-
sons that prevented a meaningful analysis of the efficacy
of the combination therapy. Because of the low occur-
rence of the HCC patients with IVC/RA metastases, it is
difficult to recruit more patients to perform a perspec-
tive comparative study.
Conclusions
The combination of TACE and EBRT can be safely per-
formed in HCC patients with an IVC or RA tumor
thrombus, resulting in a median survival of 21 months.
However, metastasis remains an unresolved issue that re-
stricts prognosis. Further investigations on systemic therap-
ies for metastatic tumors should be pursued.
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